Previous Article | Next Article 
Journal of Clinical Microbiology, December 1999, p. 3896-3900, Vol. 37, No. 12
0095-1137/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Epidemiology of Oropharyngeal Candida
Colonization and Infection in Patients Receiving Radiation for Head and
Neck Cancer
Spencer W.
Redding,1,*
Richard C.
Zellars,2
William R.
Kirkpatrick,3
Robert K.
McAtee,3
Marta A.
Caceres,3
Annette W.
Fothergill,4
Jose L.
Lopez-Ribot,3
Cliff W.
Bailey,1
Michael G.
Rinaldi,4 and
Thomas F.
Patterson3
Department of General
Dentistry,1 Department of Radiology,
Division of Radiation Oncology,2
Department of Medicine, Division of Infectious
Diseases,3 and Department of
Pathology,4 The University of Texas Health
Science Center at San Antonio, San Antonio, Texas 78284-7881
Received 2 July 1999/Returned for modification 5 August
1999/Accepted 21 August 1999
 |
ABSTRACT |
Oral mucosal colonization and infection with Candida
are common in patients receiving radiation therapy for head and neck cancer. Infection is marked by oral pain and/or burning and can lead to
significant patient morbidity. The purpose of this study was to
identify Candida strain diversity in this population by using a chromogenic medium, subculturing, molecular typing, and antifungal susceptibility testing of clinical isolates. These results
were then correlated with clinical outcome in patients treated with
fluconazole for infection. Specimens from 30 patients receiving
radiation therapy for head and neck cancer were cultured weekly for
Candida. Patients exhibiting clinical infection were treated with oral fluconazole. All isolates were plated on CHROMagar Candida and RPMI medium, subcultured, and submitted for antifungal susceptibility testing and molecular typing. Infections occurred in
27% of the patients and were predominantly due to Candida
albicans (78%). Candida carriage occurred in 73% of
patients and at 51% of patient visits. Yeasts other than C. albicans predominated in carriage, as they were isolated from
59% of patients and at 52% of patient visits. All infections
responded clinically, and all isolates were susceptible to fluconazole.
Molecular typing showed that most patients had similar strains
throughout their radiation treatment. One patient, however, did show
the acquisition of a new strain. With this high rate of infection
(27%), prophylaxis to prevent infection should be evaluated for these patients.
 |
INTRODUCTION |
Oropharyngeal candidiasis is a
common infection in patients receiving cancer therapies. Oral mucosal
colonization (up to 93%) and infection (ranging from 17 to 29%) with
Candida are particularly common in patients receiving
radiation therapy for head and neck cancer (3, 17, 24).
Compromised salivary function secondary to destruction of glandular
tissue by radiation is thought to be a major factor leading to
Candida infection (3, 5). This infection is
marked by oral pain and/or burning and can lead to significant patient
morbidity (3).
Determination of the epidemiology of Candida isolates in
patients receiving head and neck radiation has traditionally involved taking individual cultures and identifying yeasts to the species level,
as well as using techniques to identify specific yeast strains with
serotyping and biotyping. In the past Candida albicans has
been by far the most predominant organism isolated (24). However, taking a single culture and performing the above-mentioned tests may not be sensitive in distinguishing all C. albicans
strains or non-C. albicans Candida present at colonization
and/or infection (9, 10). It appears from other populations,
primarily human immunodeficiency virus (HIV) patients, that by
employing subculturing of multiple colonies from each culture and by
using molecular techniques with these subcultures, a more accurate
picture of the epidemiology of these organisms can be developed
(9, 10, 15, 19). Also, the use of a chromogenic medium will
allow the identification of multiple Candida species on the
basis of colony color (14).
Molecular typing techniques have been very useful for determining the
identities of serial isolates with recurrent candidal infections
(9, 10, 15, 19). In many patients, a single unique strain of
Candida may persist over many months and be associated with
recurrent infection or colonization (15, 18, 19). This suggests that recurrence may be due to failure of therapy to eradicate the initial organism. However, in other studies with cancer patients and with HIV-infected patients, a new strain of C. albicans
or a different Candida species with recurrent infection or
colonization has been observed (15, 19). As many as 50% of
HIV patients may develop infection due to strains distinct from that
causing the initial infection (15, 19). Molecular typing
techniques have also been helpful in determining Candida
strain diversity of individual cultures (10, 15, 19). HIV
patients may have as many as three different Candida strains
from any one culture of colonization or infection (15, 19).
Fluconazole is the predominant medication utilized to treat
oropharyngeal candidiasis. It has been studied extensively for HIV
patients (12, 16). Development of resistance to fluconazole in these patients has become a growing concern and usually is correlated with the degree of immunosuppression and the total dose of
drug (1, 20, 21). Fluconazole has also been used effectively
to treat this infection in patients receiving head and neck radiation,
as the predominant organism has been C. albicans (3,
17). However, recently an increase in non-C. albicans Candida has been reported in head and neck cancer patients
receiving radiation therapy (17). The issue of resistance to
fluconazole has not been evaluated closely for this patient population.
If resistance to fluconazole does occur, its occurrence may be due to
the presence of yeasts other than C. albicans which are less susceptible to fluconazole, or it may result from the development of
resistance in a previously susceptible C. albicans strain. While both of these resistance mechanisms may occur in patients with
HIV infection (15), the operative mechanism in patients with
head and neck cancer has not been established.
Oral Candida strain diversity, as determined by using a
chromogenic medium, subculturing, and molecular techniques, and the potential effectiveness of fluconazole treatment for oropharyngeal candidiasis, as determined by antifungal susceptibility testing, have
not been closely studied for patients receiving radiation to treat head
and neck cancer. The purpose of this study was to evaluate
Candida diversity and to correlate it with fluconazole treatment in this patient population.
 |
MATERIALS AND METHODS |
Patients.
Thirty patients receiving a 6-week course of
radiation therapy for treatment of head and neck cancer were enrolled
in the study. Patients were examined for signs of oropharyngeal
candidiasis at baseline and weekly thereafter during their radiation
treatment. Oral cultures were obtained at each visit and from any
clinical infection. Infection was defined as positive clinical signs of white intraoral plaques confirmed by use of a 10% KOH preparation and/or positive culture. Patients with infection were treated with
fluconazole (200 mg [loading dose] and 100 mg/day for 7 days to 14 days). If a clinical cure was not achieved in 14 days, the dosage was
increased up to 800 mg/day to achieve a clinical cure (21).
Fungal cultures employed an oral swab and a swish sample of 10 ml of
normal saline instilled in the mouth for 10 s and then collected
in a sterile container. These samples were plated on CHROMagar Candida-
and RPMI-based medium (20). Yeasts were identified by
standard techniques. For all cultures, three to five yeast colonies
from primary plates were picked and stored on Sabouraud dextrose slants
for antifungal susceptibility testing and molecular typing.
Antifungal susceptibility testing.
Three to five colonies
from each sample were submitted for broth macro- and microdilution MIC
determinations, to correlate with appearance on fluconazole-containing
chromogenic medium as either susceptible or resistant (14).
Testing of fluconazole MICs by the National Committee for Clinical
Laboratory Standards (NCCLS) method was performed at the Fungus Testing
Laboratory, University of Texas Health Science Center, San Antonio
(6, 13).
Genotypic identification tests.
All C. albicans
isolates were karyotyped. Selected isolates were also identified by
using restriction fragment length polymorphism (RFLP) analysis and the
moderately repetitive Ca 3 probe.
(i) Electrophoretic karyotyping.
C. albicans isolates
were plated on Sabouraud dextrose agar and grown at 30°C for 48 h. Colonies were suspended in 2 ml of 75 mM NaCl-25 mM EDTA to a
turbidity of approximately a 2.0 McFarland standard. The suspension was
centrifuged at 230 × g for 10 min, and the pellet was
resuspended in 1 ml of 75 mM NaCl-25 mM EDTA. Plugs were made by
mixing together at 37°C (i) 1 ml of 1.5% low-melting-point agarose
in 125 mM EDTA (pH 7.5), (ii) 75 µl of 2,000-U/ml Zymolyase-20T (ICN
Biomedicals, Inc., Aurora, Ohio), and (iii) 1 ml of the cell suspension. This mixture was distributed into plug molds and
refrigerated for 1 h at 4°C. Spheroplasts were made by placing
plugs in 4 ml of 0.5 M EDTA (pH 9.0)-7.5%
-mercaptoethanol. Plugs
were incubated overnight at 37°C and then rinsed with 5 ml of 50 mM
EDTA, pH 7.5. Four milliliters of ESP (0.5 M EDTA, 10% sarcosyl, 20 µg of proteinase K per ml) solution was added to each tube and
incubated at 50°C overnight. Plugs were refrigerated at 4°C for
1 h. The chromosomes were resolved on a 1.0% low-melting-point
agarose gel with a contour-clamped homogenous electric field (CHEF)
(CHEF-DR III; Bio-Rad, Hercules, Calif.). The switching times used for CHEF electrophoresis were (i) 120 s at 4.5 V/cm for 21 h;
(ii) 300 s at 4.5 V/cm for 18 h; and (iii) 300 s at 3.4 V/cm for 28 h. After electrophoresis, the gels were stained with
ethidium bromide, illuminated under UV light, and photographed
(2).
(ii) RFLP.
RFLP patterns were generated by digestion of
genomic DNA with SfiI or EcoRI (Boehringer
Mannheim, Indianapolis, Ind.) and subsequent separation of DNA
fragments by pulsed-field gel electrophoresis. Briefly, plugs prepared
as described above were incubated in the presence of the corresponding
restriction endonuclease. After digestion, the plugs were loaded in
wells of a 0.8% agarose gel. This gel was placed in a CHEF gel chamber
(DR III; Bio-Rad), and electrophoresis was performed with the following
parameters: for SfiI, pulse times were ramped from 5 to
35 s for 24 h at 6 V/cm, and for EcoRI, pulse
times were ramped from 5 to 35 s for 18 h at 4.5 V/cm. After
the run, gels were stained with ethidium bromide and photographed
(26).
(iii) Southern hybridization with the moderately repetitive probe
Ca 3.
The materials present in the RFLP gels were transferred to
nylon membranes (Nytran; Schleicher and Schuell, Keene, N.H.) overnight by using a Turboblotter apparatus and 20× SSC (1× SSC is 0.15 M NaCl
plus 0.015 M sodium citrate) buffer (Schleicher and Schuell). Subsequently, materials present in the nylon membranes were hybridized with a Ca 3 probe radioactively labeled by random priming (Random Primers DNA Labeling System; Gibco-BRL, Gaithersburg, Md.).
Prehybridization and hybridization were performed with Rapid-hyb buffer
(Amersham Life Science Inc., Arlington Heights, Ill.) according to the
manufacturer's instructions. The membranes were then washed and
exposed to autoradiography film (Du Pont, Wilmington, Del.)
(23).
(a) Documentation.
Pictures of the gels or films were
scanned with a Kodak EDAS 120 digital camera and imaging processing
system. For preparation of the figures, digital images were processed
by using the Photo Shop program (Adobe Systems Inc., Mountain View,
Calif.).
(b) Visual analysis of band patterns.
The fingerprints
obtained were compared for similarity by visual inspection of band
patterns. Sizes of DNA fragments amplified by PCR were determined by
direct comparison with the DNA marker (100-bp ladder; Gibco-BRL).
Fingerprints were considered highly similar when all visible bands
obtained had the same migration distance for each isolate. Variations
in the intensity and shape of bands among isolates were not considered
differences. The presence or absence of more than two distinct bands
was considered a difference (11).
(c) Computer-assisted analysis of fingerprinting patterns.
All fingerprints were analyzed with the Molecular Analyst
fingerprinting software (Bio-Rad) by using band-based cluster analysis. Dendrograms were generated by the hierarchic unweighted pair group method using arithmetic averages cluster algorithm. Fingerprint analysis and the methods and algorithms used in this study were performed according to the manufacturer's instructions.
 |
RESULTS |
Patient diseases and radiation doses are listed in Table
1. The radiation dose at the last visit
in this study ranged from 1,000 to 7,200 cGy, with a mean of 5,595 cGy.
Four patients did not complete the study, as they dropped out prior to
finishing their radiation treatment. Candida infections
occurred in 8 of 30 patients (27%) and at 9 of 185 patient visits
(5%). C. albicans alone was isolated in seven of nine
epidoses of infection (78%). C. albicans and a yeast other
than C. albicans were isolated in one of nine episodes of
infection (11%). A yeast other than C. albicans alone was
isolated in one of nine episodes of infection (11%). Overall, 22 of 30 patients (73%) and 95 of 185 patient visits (51%) were positive for
Candida carriage (infection and colonization). C. albicans alone was isolated from 9 of 22 patients (41%) and at 46 of 95 patient visits (48%). Yeasts other than C. albicans
were detected in 13 of 22 patients (59%) with positive cultures and at
49 of 95 patient visits with positive cultures (52%). Ten different
yeast species were isolated (Tables 2 and 3). Mixed cultures of C. albicans and other yeasts were isolated from 6 of 22 patients
(27%) and at 15 of 95 patients visits (16%). Yeasts other than
C. albicans alone were isolated from 7 of 22 patients (32%)
and at 34 of 95 patient visits (36%) (Table 2).
View this table:
[in this window]
[in a new window]
|
TABLE 3.
Susceptibilities of yeasts other than C. albicans to fluconazole as determined by NCCLS broth
macrodilution testing
|
|
All infections involving C. albicans alone responded to
fluconazole therapy at a dosage of 100 mg/day for 7 to 14 days. All of
the C. albicans isolates recovered on symptomatic infection as well as asymptomatic colonizing isolates were susceptible to fluconazole in vitro (Table 4). Patient 7 showed fluconazole MICs of >64 µg/ml but these probably represented
trailing endpoints, as the organism was susceptible to fluconazole on
chromogenic agar containing fluconazole (22). Patient 20 exhibited one relapse of infection, but the organism remained
susceptible and responded clinically to standard fluconazole therapy at
100 mg/day.
View this table:
[in this window]
[in a new window]
|
TABLE 4.
Susceptibilities of C. albicans isolates to
fluconazole as determined by NCCLS broth macrodilution testing
|
|
There was a wide range in the susceptibility of yeasts other than
C. albicans, with MICs ranging from <0.125 to >64 µg/ml (Table 3). Patient 2, infected with Candida rugosa, required 200 mg of fluconazole per day to achieve a clinical cure. His fluconazole MICs were elevated (4 to 8) but still within the
susceptible range. Patient 1 exhibited a mixed infection and
colonization pattern with C. albicans and Candida
dubliniensis. Treatment of the infection eradicated the C. albicans after 7 days, but clinical signs were still present and
C. dubliniensis was cultured. After an additional 7 days of
therapy, the patient was clinically cured and all cultures were
negative for yeasts. All isolates of both organisms were susceptible to fluconazole.
Molecular typing was performed for all 12 patients who showed
persistent C. albicans carriage. Karyotyping was performed
on isolates from all 12 patients. RFLP analysis and Southern
hybridization with the moderately repetitive Ca 3 probe were performed
on isolates from selected patients. Serial isolates appeared to be
similar for all patients except patient 24, who displayed two distinct strains. In this patient common strains were seen at all visits except
visit three, where a new strain emerged with the original strain and
clinical infection was present. The patient was successfully treated
with fluconazole, and the new strain was eradicated. However, the
patient remained colonized with the original strain for four more
visits. All of these isolates appeared to be susceptible to fluconazole
in vitro. Figure 1 shows karyotype, RFLP,
and Southern hybridization results for patient 20. Figure
2 shows karyotype results for patient 24.

View larger version (93K):
[in this window]
[in a new window]
|
FIG. 1.
Isolates from patient 20. Each lane represents a
separate subisolate collected over six visits when cultures were
positive. (A) Karyotype; (B) RFLP analysis with SfiI
digestion of genomic DNA; (C) fingerprinting analysis with the Ca 3 probe. All isolates appear to be similar.
|
|

View larger version (85K):
[in this window]
[in a new window]
|
FIG. 2.
Isolates from patient 24. Each lane represents the
karyotype analysis of a separate subisolate collected over seven visits
when cultures were positive. Lanes 5 and 7 show the emergence of a new
strain at visit 3. All other isolates appear to be similar, including
that in lane 6, which was also from visit 3.
|
|
 |
DISCUSSION |
The epidemiology of C. albicans and other yeasts from
the oropharynx of patients receiving radiation for head and neck cancer is quite varied. C. albicans was the predominant organism
associated with symptomatic infection. C. albicans alone was
present in all but two of nine infections. It is of interest that in a
mixed infection of C. albicans and the recently described
oral pathogen C. dubliniensis, the C. dubliniensis was the presumed causative agent of the infection, as
clinical infection persisted with the presence of C. dubliniensis alone. C. dubliniensis has been associated with oropharyngeal candidiasis (25) and recently has been
isolated from HIV-infected patients in North America (8).
However, to our knowledge this is the first report of an oral infection
with C. dubliniensis in a patient receiving head and neck
radiation. The other infection due to yeasts other than C. albicans alone was due to C. rugosa and was an isolate
which was susceptible in vitro to fluconazole and clinically responded
to fluconazole therapy.
Candida colonization was common and was detected in 73% of
patients and in 51% of patient visits. However, colonization due to
C. albicans alone occurred in only 48% of all positive
cultures and 41% of positive patients. Yeasts other than C. albicans alone were detected in 36% of all positive cultures and
32% of patients. Fifteen patients were free of yeast at the initial
visit. Eight patients remained free of yeast colonization, and seven
patients became colonized after the initial visit. This data
strengthens earlier reports of a significant role for yeasts other than
C. albicans in oropharyngeal carriage in patients receiving
head and neck radiation (17). Infection was due to yeasts
other than C. albicans in 25% of the patients, and one of
these infections required an increased dose of fluconazole to achieve a
clinical response. Thus, it would seem prudent to search for these
organisms in patients who do not respond to standard therapy. If
culturing is employed, the use of chromogenic agar may be helpful in
this identification (14). Antifungal susceptibility testing
may also be useful in guiding antifungal therapy (21).
Fluconazole appeared to be very effective in treating all infected
patients. All infections were treated successfully with the standard
dose, except for the one patient with C. rugosa, which
responded to 200 mg of fluconazole. Of the C. albicans
isolates, all appeared to be susceptible in vitro to fluconazole except
the one that apparently displayed trailing endpoints. One of the eight
patients with infection relapsed once with the same strain of C. albicans, but both episodes of infection were successfully treated
with fluconazole at 100 mg/day. In contrast, yeasts other than C. albicans exhibited significant increases in fluconazole MICs. Ten
of 12 patients with non-C. albicans isolates showed
increased fluconazole MICs, ranging from 4 to >64 µg/ml.
Molecular characterization of serial isolates from multiple cultures
showed that the majority of patients retain similar strains of C. albicans over time. However, emergence of new strains does occur.
Interestingly, in patient 24 the emergence of a new strain corresponded
to clinical infection although the original strain was present as well.
All other cultures before and after the infection were associated
with colonization and showed the original strain only. All C. albicans isolates were susceptible to fluconazole and responded to
fluconazole therapy.
Other patient groups with an opportunistic infection rate of 27%
(e.g., bone marrow transplantation patients and HIV-infected patients)
are commonly considered for prophylaxis (4, 7, 27). Oral
mucositis associated with radiation therapy is typically very painful
and can affect oral intake and even limit the radiation dosage. The
relative role of candidiasis in this condition is not well defined.
Could elimination or significant reduction of oropharyngeal candidiasis
reduce the morbidity associated with radiation-induced mucositis?
Prophylaxis of all patients may be problematic, as the potential for
selection of resistant organisms would exist. However, preemptive
therapy may be more appropriate. All eight patients who developed
infection in this study were colonized prior to infection. Also, they
all developed their infections after they had received at least 1,000 cGy of radiation. If only such patients are targeted for preemptive
therapy, this would appear to cover all who will develop infection but
to greatly reduce drug exposure among all patients. Our group is now
evaluating preemptive therapy in this population.
 |
ACKNOWLEDGMENTS |
This work was supported by a grant from Pfizer Inc. (to S.W.R.);
by Public Health Service grants 1 R01 DE11381 (to T.F.P.), 1 R29
AI42401 (to J.L.L.-R.), and M01-RR-01346 for the Frederic C. Bartter
General Clinical Research Center; and by a Department of Veterans
Affairs Postdoctoral Fellowship in Dental Research (to S.W.R.).
Chromogenic medium was provided by Chromagar Co. (Paris, France).
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
General Dentistry, The University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Dr., San Antonio, TX 78284-7881. Phone: (210)
567-3798. Fax: (210) 567-6721. E-mail: redding{at}uthscsa.edu.
 |
REFERENCES |
| 1.
|
Boken, D. J.,
S. Swindels, and M. G. Rinaldi.
1993.
Fluconazole-resistant Candida albicans.
Clin. Infect. Dis.
17:1018-1021[Medline].
|
| 2.
|
Doebbling, B. N.,
R. F. Lehmenn,
R. J. Hollis,
L. C. Wu,
A. F. Widmer,
A. Voss, and M. A. Pfaller.
1993.
Comparison of pulsed-field gel electrophoresis with isoenzyme profiles as a typing system for Candida tropicalis.
Clin. Infect. Dis.
16:377-383[Medline].
|
| 3.
|
Fotos, P. G., and J. W. Hellstein.
1992.
Candida and candidosis.
Dent. Clin. N. Am.
36:857-878[Medline].
|
| 4.
|
Goodman, J. L.,
D. J. Winston,
R. A. Greenfield, et al.
1992.
A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation.
N. Engl. J. Med.
362:845-851.
|
| 5.
|
Haveman, C. W., and S. W. Redding.
1998.
Dental management and treatment of xerostomic patients.
Texas Dent. J.
115:43-56.
|
| 6.
|
Isenberg, H. D. (ed.).
1992.
Clinical microbiology procedures handbook.
American Society for Microbiology, Washington, D.C.
|
| 7.
|
Just-Nübling, G.,
G. Gentschew,
K. Mebner, et al.
1991.
Fluconazole prophylaxis of recurrent oral candidiasis in HIV-positive patients.
Eur. J. Clin. Microbiol. Infect. Dis.
10:917-921[Medline].
|
| 8.
|
Kirkpatrick, W. R.,
R. K. McAtee,
J. L. Lopez-Ribot,
A. W. Fothergill,
D. I. McCarthy,
M. D. Rinaldi, and T. F. Patterson.
1998.
Detection of Candida dubliniensis in oropharyngeal samples from human immunodeficiency virus-infected patients in North America by primary CHROM agar Candida screening and susceptibility testing of isolates.
J. Clin. Microbiol.
36:3007-3012[Abstract/Free Full Text].
|
| 9.
|
López-Ribot, J. L.,
R. K. AcAtee,
L. N. Lee,
W. R. Kirkpatrick,
T. C. White,
D. Sanglard, and T. F. Patterson.
1998.
Distinct patterns of gene expression associated with development of fluconazole resistance in serial Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis.
Antimicrob. Agents Chemother.
42:2932-2937[Abstract/Free Full Text].
|
| 10.
| López-Ribot, J. L., R. K. McAtee,
L. N. Lee, W. R. Kirkpatrick, M. G. Rinaldi, and T. F. Patterson. Molecular mechanisms of resistance to azoles in
Candida albicans: multiple resistant phenotypes coexist
during the same episode of oropharyngeal candidiasis in human
immunodeficiency virus-infected patients.Antimicrob. Agents
Chemother., in press.
|
| 11.
|
Magee, P. T.,
L. Bowdin, and J. Staudinger.
1992.
Comparison of molecular typing methods for Candida albicans.
J. Clin. Microbiol.
30:2674-2679[Abstract/Free Full Text].
|
| 12.
|
Meunier, F.,
M. Aoun, and M. Gerard.
1990.
Therapy for oropharyngeal candidiasis in the immunocompromised host: a randomized double-blind study of fluconazole vs ketoconazole.
Rev. Infect. Dis.
12(Suppl. 3):S364-S368.
|
| 13.
|
National Committee for Clinical Laboratory Standards.
1997.
Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard. NCCLS document M27-A.
National Committee for Clinical Laboratory Standards, Wayne, Pa.
|
| 14.
|
Patterson, T. F.,
S. G. Revankar,
W. R. Kirkpatrick,
O. Dib,
A. W. Fothergill,
S. W. Redding,
D. A. McGough, and M. G. Rinaldi.
1996.
A simple method for detecting fluconazole-resistant yeasts with chromogenic agar.
J. Clin. Microbiol.
34:1794-1797[Abstract].
|
| 15.
|
Pfaller, M. A.,
J. Rhine-Chalberg,
S. W. Redding,
J. Smith,
G. Farinacci,
A. W. Fothergill, and M. G. Rinaldi.
1994.
Variations in fluconazole susceptibility and electrophoretic karyotype among oral isolates of Candida albicans from patients with AIDS and oral candidiasis.
J. Clin. Microbiol.
32:59-64[Abstract/Free Full Text].
|
| 16.
|
Pons, V.,
D. Greenspan,
M. Debruin, and the Multicenter Study Group.
1993.
Therapy for oropharyngeal candidiasis in HIV-infected patients: a randomized prospective multicenter study of oral fluconazole versus clotrimazole troches.
J. Acquir. Immune Defic. Syndr.
6:2322-2326.
|
| 17.
|
Ramirez-Amador, V.,
S. Silverman,
P. Mayer,
M. Tyler, and J. Quivery.
1997.
Candidal colonization and oral candidiasis in patients undergoing oral and pharyngeal radiation therapy.
Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod.
84:149-153[Medline].
|
| 18.
|
Redding, S.,
J. Smith,
G. Farinacci,
M. Rinaldi,
A. Fothergill,
J. Rhine-Chalberg, and M. Pfaller.
1994.
Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS.
Clin. Infect. Dis.
18:240-242[Medline].
|
| 19.
|
Redding, S. W.,
M. A. Pfaller,
S. A. Messer,
J. A. Smith,
J. Prows,
L. L. Bradley,
A. W. Fothergill, and M. G. Rinaldi.
1997.
Variations in fluconazole susceptibility and DNA subtyping of multiple Candida albicans colonies from patients with AIDS and oral candidiasis suffering one or more episodes of infection.
J. Clin. Microbiol.
37:1761-1765.
|
| 20.
|
Revankar, S. G.,
W. R. Kirkpatrick,
R. McAtee,
O. P. Dib,
A. W. Fothergill,
S. W. Redding,
D. A. McGough,
M. G. Rinaldi, and T. F. Patterson.
1996.
Detection and significance of fluconazole resistance in oropharyngeal candidiasis in HIV-infected patients.
J. Infect. Dis.
174:821-827[Medline].
|
| 21.
|
Revankar, S. G.,
O. P. Dib,
W. R. Kirkpatrick,
R. K. McAtee,
A. W. Fothergill,
M. G. Rinaldi,
S. W. Redding, and T. F. Patterson.
1998.
Clinical evaluation and microbiology of oropharyngeal infection due to fluconazole resistant Candida in human immunodeficiency virus-infected patients.
Clin. Infect. Dis.
26:960-963[Medline].
|
| 22.
|
Revankar, S. G.,
W. R. Kirkpatrick,
R. F. McAtee,
A. W. Fothergill,
S. W. Redding,
M. G. Rinaldi, and T. F. Patterson.
1998.
Interpretation of trailing endpoints in antifungal susceptibility testing by the National Committee for Clinical Laboratory Standards method.
Anticrob. Agents Chemother.
36:153-156.
|
| 23.
|
Schmid, J.,
E. Voss, and D. R. Soll.
1990.
Computer-assisted methods for assessing strain relatedness in Candida albicans by fingerprinting with the moderately repetitive sequence Ca 3.
J. Clin. Microbiol.
28:1236-1243[Abstract/Free Full Text].
|
| 24.
|
Silverman, S.,
L. Luangjarmekorn, and D. Greenspan.
1984.
Occurrence of oral Candida in irradiated head and neck cancer patients.
J. Oral Med.
39:194-196[Medline].
|
| 25.
|
Sullivan, D.,
K. Haynes,
J. Billie,
P. Boerlin,
L. Rodero,
S. Lloyd,
M. Herman, and D. Coleman.
1997.
Widespread geographic distribution of oral Candida dubliniensis strains in human immunodeficiency virus-infected individuals.
J. Clin. Microbiol.
35:960-964[Abstract].
|
| 26.
|
Vasquez, J. A.,
A. Beckley,
J. D. Sobel, and J. J. Zervos.
1991.
Comparison of restriction enzyme analysis and pulsed-field gradient gel electrophoresis as typing systems for Candida albicans.
J. Clin. Microbiol.
29:962-967[Abstract/Free Full Text].
|
| 27.
|
Winston, D. J.,
P. H. Chandrasekar,
H. M. Lazarus,
J. L. Goodman,
J. L. Silber,
H. Horowitz, et al.
1993.
Fluconazole prophylaxis of fungal infection in patients with acute leukemia. Results of a placebo-controlled, double-blind, multicenter trail.
Ann. Intern. Med.
118:495-503[Abstract/Free Full Text].
|
Journal of Clinical Microbiology, December 1999, p. 3896-3900, Vol. 37, No. 12
0095-1137/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Jang, W. S., Li, X. S., Sun, J. N., Edgerton, M.
(2008). The P-113 Fragment of Histatin 5 Requires a Specific Peptide Sequence for Intracellular Translocation in Candida albicans, Which Is Independent of Cell Wall Binding. Antimicrob. Agents Chemother.
52: 497-504
[Abstract]
[Full Text]
-
Scully, C., Ettinger, R. L.
(2007). The Influence of Systemic Diseases on Oral Health Care in Older Adults. Journal of the American Dental Association
138: 7S-14S
[Abstract]
[Full Text]
-
Li, L., Redding, S., Dongari-Bagtzoglou, A.
(2007). Candida glabrata, an Emerging Oral Opportunistic Pathogen. JDR
86: 204-215
[Abstract]
[Full Text]
-
Rautemaa, R., Rusanen, P., Richardson, M., Meurman, J. H.
(2006). Optimal sampling site for mucosal candidosis in oral cancer patients is the labial sulcus.. J Med Microbiol
55: 1447-1451
[Abstract]
[Full Text]
-
Dongari-Bagtzoglou, A., Fidel, P.L. Jr.
(2005). The Host Cytokine Responses and Protective Immunity in Oropharyngeal Candidiasis. JDR
84: 966-977
[Abstract]
[Full Text]
-
Murray, C K, Beckius, M L, Green, J A, Hospenthal, D R
(2005). Use of chromogenic medium in the isolation of yeasts from clinical specimens. J Med Microbiol
54: 981-985
[Abstract]
[Full Text]
-
Burn, A. K., Fothergill, A. W., Kirkpatrick, W. R., Coco, B. J., Patterson, T. F., McCarthy, D. I., Rinaldi, M. G., Redding, S. W.
(2004). Comparison of Antifungal Susceptibilities to Fluconazole and Voriconazole of Oral Candida glabrata Isolates from Head and Neck Radiation Patients. J. Clin. Microbiol.
42: 5846-5848
[Abstract]
[Full Text]
-
Ahmad, S., Khan, Z., Mokaddas, E., Khan, Z. U.
(2004). Isolation and molecular identification of Candida dubliniensis from non-human immunodeficiency virus-infected patients in Kuwait. J Med Microbiol
53: 633-637
[Abstract]
[Full Text]
-
Wunder, D., Dong, J., Baev, D., Edgerton, M.
(2004). Human Salivary Histatin 5 Fungicidal Action Does Not Induce Programmed Cell Death Pathways in Candida albicans. Antimicrob. Agents Chemother.
48: 110-115
[Abstract]
[Full Text]
-
Horvath, L. L., Hospenthal, D. R., Murray, C. K., Dooley, D. P.
(2003). Direct Isolation of Candida spp. from Blood Cultures on the Chromogenic Medium CHROMagar Candida. J. Clin. Microbiol.
41: 2629-2632
[Abstract]
[Full Text]
-
Redding, S. W., Kirkpatrick, W. R., Saville, S., Coco, B. J., White, W., Fothergill, A., Rinaldi, M., Eng, T., Patterson, T. F., Lopez-Ribot, J.
(2003). Multiple Patterns of Resistance to Fluconazole in Candida glabrata Isolates from a Patient with Oropharyngeal Candidiasis Receiving Head and Neck Radiation. J. Clin. Microbiol.
41: 619-622
[Abstract]
[Full Text]
-
Hospenthal, D. R., Murray, C. K., Beckius, M. L., Green, J. A., Dooley, D. P.
(2002). Persistence of Pigment Production by Yeast Isolates Grown on CHROMagar Candida Medium. J. Clin. Microbiol.
40: 4768-4770
[Abstract]
[Full Text]
-
Martinez, M., Lopez-Ribot, J. L., Kirkpatrick, W. R., Coco, B. J., Bachmann, S. P., Patterson, T. F.
(2002). Replacement of Candida albicans with C. dubliniensis in Human Immunodeficiency Virus-Infected Patients with Oropharyngeal Candidiasis Treated with Fluconazole. J. Clin. Microbiol.
40: 3135-3139
[Abstract]
[Full Text]
-
Redding, S. W., Kirkpatrick, W. R., Coco, B. J., Sadkowski, L., Fothergill, A. W., Rinaldi, M. G., Eng, T. Y., Patterson, T. F.
(2002). Candida glabrata Oropharyngeal Candidiasis in Patients Receiving Radiation Treatment for Head and Neck Cancer. J. Clin. Microbiol.
40: 1879-1881
[Abstract]
[Full Text]
-
Bartie, K. L., Williams, D. W., Wilson, M. J., Potts, A. J. C., Lewis, M. A. O.
(2001). PCR Fingerprinting of Candida albicans Associated with Chronic Hyperplastic Candidosis and Other Oral Conditions. J. Clin. Microbiol.
39: 4066-4075
[Abstract]
[Full Text]
-
Botterel, F., Desterke, C., Costa, C., Bretagne, S.
(2001). Analysis of Microsatellite Markers of Candida albicans Used for Rapid Typing. J. Clin. Microbiol.
39: 4076-4081
[Abstract]
[Full Text]
-
Camidge, D R
(2001). The causes of dysphagia in carcinoma of the lung. JRSM
94: 567-572
[Abstract]
[Full Text]
-
Leung, W. K., Dassanayake, R. S., Yau, J. Y. Y., Jin, L. J., Yam, W. C., Samaranayake, L. P.
(2000). Oral Colonization, Phenotypic, and Genotypic Profiles of Candida Species in Irradiated, Dentate, Xerostomic Nasopharyngeal Carcinoma Survivors. J. Clin. Microbiol.
38: 2219-2226
[Abstract]
[Full Text]